Evidence map›Paper›PMID 38411056›Full record

ArticleMicrobiology spectrum2024

Robust and sensitive amplicon-based whole-genome sequencing assay of respiratory syncytial virus subtype A and B.

Tiina Talts, Lucy G Mosscrop, David Williams, John S Tregoning, Whitney Paulo, Arinder Kohli, Thomas C Williams, Katja Hoschler, Joanna Ellis, Simon de Lusignan and 1 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Tiina TaltsUK Health Security Agency, London, United Kingdom.ORCID 0009-0008-1534-278X
Lucy G MosscropImperial College London, London, United Kingdom.ORCID 0000-0003-1010-7824
David WilliamsUK Health Security Agency, London, United Kingdom.
John S TregoningImperial College London, London, United Kingdom.ORCID 0000-0001-8093-8741
Whitney PauloUK Health Security Agency, London, United Kingdom.
Arinder KohliUK Health Security Agency, London, United Kingdom.
Thomas C WilliamsUniversity of Edinburgh, Edinburgh, United Kingdom.
Katja HoschlerUK Health Security Agency, London, United Kingdom.
Joanna EllisUK Health Security Agency, London, United Kingdom.
Simon de LusignanUniversity of Oxford, Oxford, United Kingdom.
Maria ZambonUK Health Security Agency, London, United Kingdom.
UK Health Security Agency · GBImperial College London · GBUniversity of Edinburgh · GBUniversity of Oxford · GB

Funding

National Institute for Health Research Health Protection Research Unit (NIHR HPRU) NIHR200927
6 · The paper itself

Abstract

Prevention of respiratory syncytial virus (RSV) infection is now a global health priority, with a long-acting monoclonal antibody and two RSV vaccines recently licenced for clinical use. Most licenced and candidate interventions target the RSV fusion (RSV-F) protein. New interventions may be associated with the spread of mutations, reducing susceptibility to antibody neutralization in RSV-F. There is a need for ongoing longitudinal global surveillance of circulating RSV strains. To achieve this large-scale genomic surveillance, a reliable, high-throughput RSV sequencing assay is required. Here we report an improved high-throughput RSV whole-genome sequencing (WGS) assay performed directly on clinical samples without additional enrichment, using a 4-primer-pool, short-amplicon PCR-tiling approach that is suitable for short-read sequencing platforms. Using upper respiratory tract (URT) RSV-positive clinical samples obtained from a sentinel network of primary care providers and from hospital patients (29.7% and 70.2%, respectively; IMPORTANCE: In this paper, we report an improved high-throughput respiratory syncytial virus (RSV) whole-genome sequencing (WGS) assay performed directly on clinical samples, using a 4-primer-pool, short-amplicon PCR-tiling approach that is suitable for short-read sequencing platforms. The RSV WGS approach described in this study has increased sensitivity compared to previous approaches and can be applied to clinical specimens without the requirement for enrichment. The updated approach produces sequences of high quality consistently and cost-effectively, suitable for implementation to underpin national and global programs for the surveillance of RSV genomic variation. The quality of sequence produced is essential for preparedness for new interventions in monitoring antigenic escape, where a single point mutation might lead to a reduction in antibody binding effectiveness and neutralizing activity, or indeed in the monitoring of retaining susceptibility to neutralization by existing and new interventions.

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsAntibodies, MonoclonalHigh-Throughput Nucleotide SequencingHumansViral Fusion ProteinsAntibodies, MonoclonalViral Fusion Proteinsnext-generation sequencingrespiratory syncytial viruswhole-genome sequencing

Identifiers

PMID38411056
PMCPMC10986592
OpenAlexW4392199770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.